MPS Ltd
MPS is a B2B learning and platform solutions company powering education, and research for corporates. MPS has unlocked a new growth trajectory due to the combined effect of lower attention spans, rapid growth in digital consumption, and the recent advances in AI/ML.
- Market Cap ₹ 4,562 Cr.
- Current Price ₹ 2,667
- High / Low ₹ 2,980 / 1,336
- Stock P/E 31.7
- Book Value ₹ 233
- Dividend Yield 3.11 %
- ROCE 43.0 %
- ROE 34.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.2%
- Company's working capital requirements have reduced from 86.1 days to 63.4 days
Cons
- Stock is trading at 11.4 times its book value
- The company has delivered a poor sales growth of 9.45% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 203 | 224 | 224 | 218 | 224 | 188 | 279 | 284 | 298 | 328 | 351 | 438 | 463 | |
| 127 | 134 | 136 | 135 | 137 | 127 | 186 | 182 | 178 | 187 | 215 | 271 | 276 | |
| Operating Profit | 76 | 90 | 87 | 83 | 86 | 60 | 93 | 102 | 120 | 140 | 136 | 168 | 187 |
| OPM % | 37% | 40% | 39% | 38% | 39% | 32% | 33% | 36% | 40% | 43% | 39% | 38% | 40% |
| 18 | 18 | 18 | 25 | 26 | 18 | 9 | 11 | 9 | 15 | 22 | 15 | 15 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
| Depreciation | 5 | 4 | 5 | 8 | 6 | 7 | 12 | 13 | 12 | 11 | 12 | 12 | 12 |
| Profit before tax | 89 | 104 | 101 | 101 | 106 | 70 | 88 | 98 | 117 | 144 | 145 | 169 | 187 |
| Tax % | 34% | 32% | 31% | 32% | 29% | 24% | 31% | 27% | 26% | 26% | 24% | 25% | |
| 59 | 71 | 69 | 68 | 75 | 53 | 61 | 71 | 86 | 106 | 110 | 127 | 139 | |
| EPS in Rs | 31.53 | 37.88 | 37.14 | 36.64 | 40.15 | 28.35 | 33.53 | 41.78 | 50.44 | 62.23 | 64.31 | 74.40 | 81.54 |
| Dividend Payout % | 70% | 58% | 0% | 33% | 62% | 176% | 0% | 72% | 40% | 121% | 129% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 14% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 17% |
| 3 Years: | 15% |
| TTM: | 29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 32% |
| 3 Years: | 21% |
| 1 Year: | 22% |
| Return on Equity | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 28% |
| 3 Years: | 31% |
| Last Year: | 35% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 19 | 19 | 19 | 18 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 235 | 256 | 326 | 393 | 441 | 323 | 341 | 309 | 335 | 354 | 333 | 381 |
| 0 | 0 | 0 | 0 | 0 | 11 | 12 | 11 | 7 | 4 | 4 | 57 | |
| 25 | 23 | 24 | 27 | 23 | 17 | 67 | 63 | 47 | 34 | 41 | 63 | |
| Total Liabilities | 278 | 298 | 368 | 439 | 483 | 370 | 438 | 400 | 406 | 408 | 395 | 518 |
| 22 | 24 | 26 | 31 | 26 | 30 | 83 | 80 | 74 | 69 | 69 | 90 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Investments | 177 | 193 | 253 | 331 | 308 | 195 | 130 | 122 | 131 | 148 | 136 | 223 |
| 80 | 81 | 90 | 78 | 150 | 144 | 225 | 198 | 201 | 190 | 187 | 206 | |
| Total Assets | 278 | 298 | 368 | 439 | 483 | 370 | 438 | 400 | 406 | 408 | 395 | 518 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50 | 50 | 50 | 70 | 43 | 49 | 77 | 81 | 75 | 82 | 78 | 139 | |
| -150 | -9 | -50 | -71 | -13 | 147 | -37 | 26 | 3 | 11 | 53 | -88 | |
| 104 | -49 | -0 | -0 | -27 | -172 | -49 | -113 | -69 | -92 | -138 | -49 | |
| Net Cash Flow | 3 | -9 | -1 | -0 | 3 | 24 | -9 | -6 | 9 | 1 | -7 | 1 |
| Free Cash Flow | 47 | 43 | 46 | 64 | 41 | 47 | 71 | 78 | 72 | 77 | 70 | 131 |
| CFO/OP | 100% | 97% | 94% | 121% | 84% | 112% | 104% | 111% | 86% | 86% | 84% | 104% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 59 | 63 | 60 | 62 | 63 | 75 | 63 | 60 | 54 | 79 | 72 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 59 | 59 | 63 | 60 | 62 | 63 | 75 | 63 | 60 | 54 | 79 | 72 |
| Working Capital Days | 37 | 44 | 69 | 67 | 109 | 123 | 50 | 43 | 69 | 84 | 111 | 63 |
| ROCE % | 47% | 34% | 30% | 23% | 21% | 16% | 24% | 28% | 34% | 39% | 39% | 43% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Headcount Nos. |
|
||||||||||
| North America Revenue Mix % of revenue |
|||||||||||
| Research Solutions / Content Solutions Revenue Mix % of revenue |
|||||||||||
| Top 5 Client Concentration % of revenue |
|||||||||||
| Number of Clients Billed (excl. B2C) Nos. |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Closure of Trading Window
- Trading window closes from 1 October 2026 until 48 hours after Q2 FY27 results.
-
Update On The Scheme Of Amalgamation.
- NCLT recorded shareholder and creditor approval for ADI BPO-MPS amalgamation and issued notices to authorities.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Submission of Newspaper Publication regarding the transfer of Unpaid/Unclaimed Interim Dividend for the Financial Year 2019-20 along with the underlying Equity Shares, to the Investor …
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Announcement under Regulation 30 (LODR)-Meeting Updates
- Video recording of MPS Limited’s 56th AGM held on 04 September 2026 is now available on the website.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from nse
Concalls
-
Jul 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript REC
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT
-
Jul 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Mar 2024Transcript
-
Jan 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Oct 2021PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Jan 2021PPT
-
Nov 2020PPT
-
Aug 2020PPT
-
Aug 2020PPT
-
May 2020PPT
-
May 2020PPT
-
Jan 2020PPT
-
Oct 2019PPT
-
Jul 2019PPT
-
May 2019PPT
-
May 2019PPT
-
Jan 2019PPT
-
Oct 2018PPT
-
Jul 2018PPT
-
May 2018PPT
-
Jan 2018PPT
-
Oct 2017PPT
Business Segments:[1]
a) Research Solutions (60% in FY26 vs 63% in FY25):[2]
The company’s DigiCorePro platform
provides large-scale peer review, research integrity, and production workflow solutions.
Its Research Integrity Check platform is recognized as a Top Innovator at STM AI Innovation Day 2025. It uses AI-driven tools
to detect research misconduct, including paper mills, identity fraud, and image manipulation. The AJE Digital and Rubriq platform has processed over 1 Mn manuscripts and demonstrated a 52% acceptance rate in controlled trials compared with the 32% STM industry benchmark.
b) Education Solutions (27% in FY26 vs 21% in FY25):[2]
The Unbound Intelligence Assist provides AI-powered clinical decision support integrated
into flagship education platforms like uCentral and Nursing Central. The segment also focuses on accessibility and media asset development, significantly reducing production costs by automating the creation of over 30 Million
accessible media assets annually. Additionally,
its app-based assessment solutions enable
data-driven insights into learner performance
and outcomes.
c) Corporate Learning (13% in FY26 vs 16% in FY25): [2]
This segment offers AI-driven solutions,
including real-time analytics and dash
boards to track learner engagement, performance, and business impact.
Its AI roleplays and simulations
provide adaptive practice environments
that enhance real-world skills through
interactive conversations and feedback. Additionally, BridgeAI enables scalable multilingual translation and localization
of learning content with faster, accurate,
and context-aware capabilities.